A Phase 3 interventional study of EryDex Low dose DSP and EryDex High dose DSP in Nervous System Disease and Genetic Syndrome, sponsored by Quince Therapeutics S.p.A.. Completed at 22 sites in 12 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objectives:
The objective of study was to evaluate the safety and the efficacy of EryDex (Dexamethasone sodium phosphate encapsulated in autologous erythrocytes, using the EryDex System - EDS) at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on Neurological Symptoms in Patients With Ataxia Telangiectasia.
Initial Double-Blind Treatment Period (0 to 6 Months)
Primary Efficacy Objective:
Secondary Efficacy Objectives:
Safety Objectives:
Extension Treatment Period (6-12 Months):
Primary Objective:
Secondary Objectives:
This was an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study.
This study was divided into three periods: Screening (Days -30 to -1), 6-month Initial Treatment Period (Months 1-6; Visits 1-9), and 6-month Extension Treatment Period (Months 7-12; Visits 10-15).
A total of 175 patients, of the 180 planned, met all selection criteria at baseline, and were randomized in a 1:1:1 fashion to one of the two EDS-EP dose levels or placebo.
These patients were randomly assigned to receive one of the two doses of EDS-EP or placebo, as follows:
The initial 6-month treatment period was considered complete when the endpoint assessment (at Visit 9/Month 6 or at early discontinuation) was performed for all patients. All patients who completed the assessments over the initial 6 months of the trial were eligible to continue in an additional 6-month, double-blind, placebo- controlled extension, designed to collect information on the longer-term safety and efficacy of the trial treatments.
Following completion of the 6-month Initial Treatment Period, patients that met all entry criteria were re-randomized and treated as follows:
Patients originally randomized to the Placebo group (Group 3) were re-allocated as defined at the initial randomization in equal proportions (1:1) and received either the EryDex low dose or high dose as follows:
758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.
This study's enrollment of 176 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.
Browse Nervous System Diseases studies →Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
General
Females that were:
Current participation in another clinical study.
Medical History and Current Status
Moderate or severe renal and/or hepatic impairment.
Prior/Concomitant Medication
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EDS-EP dose range of \~5-10 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment). Other Names: EryDex System end product Low dose DSP
Drug: EryDex Low dose DSP
EDS-EP dose range of \~14-22 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment). Other Names: EryDex System end product High dose DSP
Drug: EryDex High dose DSP
Patients were treated with autologous erythrocytes prepared with the EDS process using a placebo solution. Placebo was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment).
Drug: Pooled Placebo
EDS-EP dose range of \~5-10 mg DSP/infusion
Also known as: EryDex System end product
EDS-EP dose range of \~14-22 mg DSP/infusion
Also known as: EryDex System end product
EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
Also known as: Placebo EDS infusion
Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)
The International Cooperative Ataxia Rating Scale (ICARS) was an assessment of the degree of impairment in patients with cerebellar ataxia and was administered in its entirety; however, the primary efficacy assessment was based on the modified (m)ICARS, which excluded the Oculomotor domain (items 17 to 19) and items 8 to 12 of the Kinetic Functions domain of the ICARS. The mICARS was a 54 points maximum score (min 0) questionnaire divided into 3 sections: * Posture and Gait Disturbance section-7 items (min score 0, max score 34) * Kinetic Function-2 items (min score 0, max score 12) * Speech Disorder- 2 items (min score 0, max score 8). The assessment was designed to be completed within 30 minutes, and higher scores - both for total and subscores - indicate a higher level of disease impairment. The subscores are added to give the total score.
Time frame: to Month 6 (Visit 9)
Number of Patients With Improving, Stable or Worsening Score Using a Clinical Global Impression of Change (CGI-C)
The CGI-C scale assesses the change in the patient's clinical status from baseline using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Clinicians were required to conduct a full clinical interview and examination of the patient. The interview and examination assessed various aspects of the patient's appearance (grooming, evidence of falls, etc.), ataxia, cognition (orientation, calculation ability, language, ability to follow commands, memory, etc.), apraxia, dysarthria, extrapyramidal motor symptoms, activities of daily living, and mood. The higher the score the worse the outcome.
Time frame: to Month 6 (Visit 9)
Number of Patients With None to Severe (0 to 4) Scores in Clinical Global Impression of Severity (CGI-S)-Structured of Neurological Symptoms of AT
The CGI-S scale measures global severity of illness at a given point in time, and is usually rated on a 7-point, Likert-type scale ranging from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). No version of the CGI-S exists which has been specifically adapted for use in patients with A-T; therefore, a 5-point version was developed that considered the severity of the following symptoms of A-T: ataxia (walking), dysarthria, dysmetria, extrapyramidal symptoms (chorea, myoclonus, dystonia, and tremor), and eye movements. Ratings of none (0), mild (1), moderate (2), severe (3), and very severe (4) were selected based on the level of symptomatology. The higher the score the worse the outcome.
Time frame: to Visit 9 (Month 6)
Change From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF)
VABS-II was a questionnaire to assess adaptive behavior. It contained 4 domains each with 2-3 subdomains, every subdomain contained various items (questions): A) communication (receptive, expressive, written) B) daily living skills (personal, domestic, community) C) socialization (interpersonal relationships, play and leisure time, coping skills) D) motor skills (gross motor, fine motor). The expanded version of the VABS consisted of 540 items, 261 of which used in this trial. The possible score for each item was from 0 to 4 based on whether the patient performed the activity "never", "rarely", "sometimes", "often" or "almost always". At the end of each domain section, a total score (the sum of the score for each item) was calculated. Domain A: min score 0, max score 572. Domain B: 0 - 800. Domain C: 0 - 580. Domain D: 0 - 424. A grand total score (A+B+C+D scores) was provided (range:0-2376) The lower the score the higher the disability at each level (domains and subdomains).
Time frame: to Visit 9 (Month 6)
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 6
TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 9 ("Month 6") infusion, or \<=60 days after last dose if the subject never continued past this period.
Time frame: to Visit 9 (Month 6)
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) at Month 12
TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 15 ("Month 12") infusion. Placebo patients who switched to EryDex treatment at 6 and 9 months were not added to the Extension Treatment Period safety data so that the results reported here under are for those patients who remained on placebo from the start of the study till the end of it.
Time frame: to Visit 15 (Month 12)
176 patients were randomized, and 175 patients received study drug (Safety Population or ITT). There were 164 patients in the mITT and 107 patients in the PP population. Of the 164 patients in the mITT, 54 were randomized to placebo, 56 to low dose, and 54 to high dose EryDex.The PP population excluded 57 patients that were unable to comply with the study treatment interval, mainly due to the COVID-19 pandemic and issues with traveling in India, and who did not meet the definition of the PP.
| Milestone | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF |
|---|---|---|---|
| Started | 59 | 58 | 59 |
| Participants who took the study drug | 59 | 57 | 59 |
| Modified intention to treat population - mitt | 56 | 54 | 54 |
| Safety population - saf | 59 | 57 | 59 |
| Per protocol population - pp | 36 | 38 | 33 |
| Completed visit 9 | 43 | 46 | 43 |
| Discontinued prior to visit 9 | 16 | 11 | 16 |
| Participants from month 6 to month 9 | 43 | 46 | 43 |
| Participants from month 9 to month12 | 34 | 38 | 36 |
| Completed | 34 | 38 | 36 |
| Not completed | 25 | 20 | 23 |
| Withdrew: Adverse event | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 7 | 3 | 4 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Covid-related treatment/visit delay | 15 | 13 | 17 |
| Withdrew: Physician decision | 0 | 0 | 1 |
The International Cooperative Ataxia Rating Scale (ICARS) was an assessment of the degree of impairment in patients with cerebellar ataxia and was administered in its entirety; however, the primary efficacy assessment was based on the modified (m)ICARS, which excluded the Oculomotor domain (items 17 to 19) and items 8 to 12 of the Kinetic Functions domain of the ICARS. The mICARS was a 54 points maximum score (min 0) questionnaire divided into 3 sections: * Posture and Gait Disturbance section-7 items (min score 0, max score 34) * Kinetic Function-2 items (min score 0, max score 12) * Speech Disorder- 2 items (min score 0, max score 8). The assessment was designed to be completed within 30 minutes, and higher scores - both for total and subscores - indicate a higher level of disease impairment. The subscores are added to give the total score.
| score on a scale | EryDex Low Dose DSP - mITT | EryDex High Dose DSP - mITT | Placebo - mITT |
|---|---|---|---|
| Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS) | 0.8 ± 3.56 | 1.0 ± 3.32 | 2.3 ± 5.03 |
The CGI-C scale assesses the change in the patient's clinical status from baseline using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Clinicians were required to conduct a full clinical interview and examination of the patient. The interview and examination assessed various aspects of the patient's appearance (grooming, evidence of falls, etc.), ataxia, cognition (orientation, calculation ability, language, ability to follow commands, memory, etc.), apraxia, dysarthria, extrapyramidal motor symptoms, activities of daily living, and mood. The higher the score the worse the outcome.
| Participants | EryDex Low Dose DSP - mITT | EryDex High Dose DSP - mITT | Placebo - mITT |
|---|---|---|---|
| Improvement (Scores 1-3) | 19 | 27 | 19 |
| Stable or Worsening (Scores 4-7) | 37 | 27 | 35 |
The CGI-S scale measures global severity of illness at a given point in time, and is usually rated on a 7-point, Likert-type scale ranging from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). No version of the CGI-S exists which has been specifically adapted for use in patients with A-T; therefore, a 5-point version was developed that considered the severity of the following symptoms of A-T: ataxia (walking), dysarthria, dysmetria, extrapyramidal symptoms (chorea, myoclonus, dystonia, and tremor), and eye movements. Ratings of none (0), mild (1), moderate (2), severe (3), and very severe (4) were selected based on the level of symptomatology. The higher the score the worse the outcome.
| Participants | EryDex Low Dose DSP - mITT | EryDex High Dose DSP - mITT | Placebo - mITT |
|---|---|---|---|
| CGI-S Score - 0 | 0 | 0 | 0 |
| CGI-S Score - 1 | 15 | 16 | 17 |
| CGI-S Score - 2 | 29 | 26 | 24 |
| CGI-S Score - 3 | 12 | 12 | 13 |
| CGI-S Score - 4 | 0 | 0 | 0 |
VABS-II was a questionnaire to assess adaptive behavior. It contained 4 domains each with 2-3 subdomains, every subdomain contained various items (questions): A) communication (receptive, expressive, written) B) daily living skills (personal, domestic, community) C) socialization (interpersonal relationships, play and leisure time, coping skills) D) motor skills (gross motor, fine motor). The expanded version of the VABS consisted of 540 items, 261 of which used in this trial. The possible score for each item was from 0 to 4 based on whether the patient performed the activity "never", "rarely", "sometimes", "often" or "almost always". At the end of each domain section, a total score (the sum of the score for each item) was calculated. Domain A: min score 0, max score 572. Domain B: 0 - 800. Domain C: 0 - 580. Domain D: 0 - 424. A grand total score (A+B+C+D scores) was provided (range:0-2376) The lower the score the higher the disability at each level (domains and subdomains).
| score on a scale | EryDex Low Dose DSP - mITT | EryDex High Dose DSP - mITT | Placebo - mITT |
|---|---|---|---|
| Change From Baseline of Vineland Adaptive Behavior Scale (VABS-II) Scores - Last Observation Carried Forward (LOCF) | 42.6 ± 125.95 | -26.5 ± 214.52 | 57.5 ± 200.37 |
TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 9 ("Month 6") infusion, or \<=60 days after last dose if the subject never continued past this period.
| Participants | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF |
|---|---|---|---|
| Patients With Pre- treatment AE | 14 | 16 | 14 |
| Patients With Any TEAE | 43 | 47 | 43 |
| Patients With Any Treatment-related TEAE | 15 | 21 | 15 |
| Patients With Any Serious TEAE | 6 | 7 | 7 |
| Patients With Any Serious Treatment-related TEAE | 0 | 1 | 0 |
| Patients With Any TEAE Leading to Discontinuation | 0 | 2 | 0 |
| Patients With Any TEAE Leading to Death | 0 | 0 | 0 |
TEAE = Treatment Emergent Adverse Events were any AEs started on or after the day of the first infusion through the day just prior to the day of the Visit 15 ("Month 12") infusion. Placebo patients who switched to EryDex treatment at 6 and 9 months were not added to the Extension Treatment Period safety data so that the results reported here under are for those patients who remained on placebo from the start of the study till the end of it.
| Participants | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Non-switch Placebo - SAF |
|---|---|---|---|
| Patients With Any TEAE | 45 | 50 | 15 |
| Patients With Any Treatment-related TEAE | 19 | 25 | 5 |
| Patients With Any Serious TEAE | 8 | 9 | 4 |
| Patients With Any Serious Treatment-related TEAE | 1 | 1 | 1 |
| Patients With Any TEAE Leading to Discontinuation | 1 | 2 | 0 |
| Patients With Any TEAE Leading to Death | 0 | 0 | 0 |
Collected over TEAEs were all the AEs reported up to the end of the Extension Treatment Period (Month 12). All AEs with an onset date on/after the start of the first infusion through 60 days after the last dose are included. A patient with more than one event with the same SOC is counted once. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EryDex Low Dose DSP - SAF | 0/59 (0%) | 8/59 (13.6%) | 45/59 (76.3%) |
| EryDex High Dose DSP - SAF | 0/57 (0%) | 9/57 (15.8%) | 50/57 (87.7%) |
| Non-switch Placebo - SAF | 1/19 (5.3%) | 4/19 (21.1%) | 15/19 (78.9%) |
| Placebo Patients Switch to Low Dose - Month 6 | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Placebo Patients Switch to High Dose - Month 6 | 0/9 (0%) | 1/9 (11.1%) | 8/9 (88.9%) |
| Placebo Patients Switch to Low Dose - Month 9 | 0/11 (0%) | 1/11 (9.1%) | 7/11 (63.6%) |
| Placebo Patients Switch to High Dose - Month 9 | 0/11 (0%) | 4/11 (36.4%) | 9/11 (81.8%) |
| Event | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Non-switch Placebo - SAF | Placebo Patients Switch to Low Dose - Month 6 | Placebo Patients Switch to High Dose - Month 6 | Placebo Patients Switch to Low Dose - Month 9 | Placebo Patients Switch to High Dose - Month 9 |
|---|---|---|---|---|---|---|---|
| Bacterial test positiveInvestigations | 4/59 | 6/57 | 3/19 | 1/9 | 0/9 | 1/11 | 2/11 |
| PyrexiaGeneral disorders | 0/59 | 1/57 | 0/19 | 0/9 | 1/9 | 0/11 | 0/11 |
| Hepato-Lenticular DegenerationCongenital, familial and genetic disorders | 0/59 | 0/57 | 0/19 | 0/9 | 0/9 | 0/11 | 1/11 |
| VomitingGastrointestinal disorders | 0/59 | 0/57 | 0/19 | 0/9 | 0/9 | 0/11 | 1/11 |
| Juvenile idiophatic arthritisMusculoskeletal and connective tissue disorders | 0/59 | 0/57 | 1/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| AnaemiaBlood and lymphatic system disorders | 0/59 | 1/57 | 0/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| SepsisInfections and infestations | 0/59 | 1/57 | 0/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| Aortic stenosisVascular disorders | 0/59 | 1/57 | 0/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| Herpes ZosterInfections and infestations | 1/59 | 0/57 | 0/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| Lower respiratory tract infectionInfections and infestations | 1/59 | 0/57 | 0/19 | 0/9 | 0/9 | 0/11 | 0/11 |
| Event | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Non-switch Placebo - SAF | Placebo Patients Switch to Low Dose - Month 6 | Placebo Patients Switch to High Dose - Month 6 | Placebo Patients Switch to Low Dose - Month 9 | Placebo Patients Switch to High Dose - Month 9 |
|---|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 10/59 | 13/57 | 6/19 | 1/9 | 4/9 | 3/11 | 1/11 |
| PyrexiaGeneral disorders | 15/59 | 19/57 | 3/19 | 3/9 | 2/9 | 4/11 | 2/11 |
| DiarrhoeaGastrointestinal disorders | 8/59 | 6/57 | 5/19 | 0/9 | 0/9 | 3/11 | 0/11 |
| Bacterial test positiveInvestigations | 10/59 | 10/57 | 4/19 | 1/9 | 2/9 | 1/11 | 3/11 |
| NasopharyngitisInfections and infestations | 10/59 | 11/57 | 5/19 | 1/9 | 1/9 | 1/11 | 1/11 |
| Weight increasedInvestigations | 0/59 | 1/57 | 0/19 | 2/9 | 0/9 | 0/11 | 0/11 |
| HeadacheNervous system disorders | 8/59 | 5/57 | 2/19 | 2/9 | 0/9 | 1/11 | 2/11 |
| VomitingGastrointestinal disorders | 13/59 | 11/57 | 3/19 | 0/9 | 1/9 | 1/11 | 2/11 |
| Abdominal pain upperGastrointestinal disorders | 0/59 | 0/57 | 0/19 | 1/9 | 0/9 | 0/11 | 2/11 |
| Blood iron decreasedInvestigations | 0/59 | 0/57 | 0/19 | 0/9 | 0/9 | 2/11 | 1/11 |
Safety (SAF): all patients who received any amount of randomized treatment (also referred to as the ITT ) Full Analysis Set (FAS): All randomized pts who received at least 1 dose of study medication and had at least one post-baseline efficacy assessment of the primary efficacy variable (also referred to as mITT ) Per Protocol (PP): all pts enrolled fulfilled all Inclusion/Exclusion criteria, did not have any major protocol violations, and completed the Initial Treatment Period of the study
| Age, Categorical(Participants) | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF | Total |
|---|---|---|---|---|
| <=18 years | 59 | 57 | 59 | 175 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF | Total |
|---|---|---|---|---|
| Mean | 9.5 ± 3.16 | 10.2 ± 4.86 | 10.3 ± 4.02 | 10.0 ± 4.06 |
| Sex: Female, Male(Participants) | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF | Total |
|---|---|---|---|---|
| Female | 29 | 27 | 29 | 85 |
| Male | 30 | 30 | 30 | 90 |
| Race (NIH/OMB)(Participants) | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 25 | 20 | 27 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 3 |
| White | 34 | 36 | 29 | 99 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | EryDex Low Dose DSP - SAF | EryDex High Dose DSP - SAF | Pooled Placebo - SAF | Total |
|---|---|---|---|---|
| Belgium | 1 | 2 | 0 | 3 |
| United States | 11 | 12 | 10 | 32 |
| Norway | 2 | 2 | 1 | 5 |
| Poland | 3 | 5 | 3 | 11 |
| United Kingdom | 2 | 3 | 6 | 11 |
| Italy | 1 | 2 | 1 | 4 |
| Israel | 1 | 0 | 0 | 1 |
| Australia | 1 | 3 | 1 | 5 |
| Tunisia | 3 | 3 | 2 | 8 |
| Germany | 5 | 6 | 5 | 16 |
| Spain | 7 | 2 | 4 | 13 |
| India | 22 | 18 | 26 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in May 2021, 50 months.
Results were first posted in May 2024, 2 years 11 months after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Nervous System Diseases, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 50 months is above that.
Counting every sponsor, half of 40 studies reached it within 42 months; a quarter within 28 and three quarters within 55.
Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Quince Therapeutics S.p.A.